Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Hodgkin Disease 3Sarcoma 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, Mantle-Cell 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Oligodendroglioma 1Neoplasms by Site 1Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia 1Gliosarcoma 1Glioma 1Glioblastoma 1Disease Progression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrence × abexinostat × Clear all
NCT03934567 2025-04-10

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Xynomic Pharmaceuticals, Inc.

Phase 2 Active not recruiting
87 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡